**Summary of OptiBiotix Health PLC Half-Year Report (H1 2025)**
OptiBiotix Health PLC, a life sciences company focused on developing products to reduce hunger, enhance gut health, and create healthy sugar substitutes, reported strong growth in its unaudited results for the six months ended 30 June 2025.
**Key Highlights**
1. **Revenue Growth** Sales surged 102% to £557K compared to H1 2024 (£276K), driven by increased demand across all business areas.
2. **Profitability Improvement** Gross profit margin rose to 54% (H1 2024: 40%), with gross profit up 173% to £303K.
3. **Cost Management** Administrative costs remained stable at £1.15m, despite increased operational scope.
4. **Cash Position** Strong cash balance of £1.3m, unchanged from H1 2024.
5. **Strategic Partnerships**
First order of six metric tonnes from Brenntag, the new Australian distributor.
Launched products in the USA with partners NHT Global and Nouri.
Appointed a new trading partner in China focused on TMALL sales.
6. **E-commerce Growth**
E-commerce customers increased by 38% to 5,095, driven by a 57.7% rise in Amazon orders to 4,159.
Amazon sales grew 87.6% to £93767.
7. **Post-Period Developments**
Launched SlimBiome® in Hydroxycut, the No. 1 weight loss supplement brand in the USA.
Signed a distribution agreement with a major weight management company, with product launch expected in H1 2026.
Received first orders from Meelung Trading in Taiwan and a new partner in Taiwan.
Discovered a new enzyme for SweetBiotix, significantly improving manufacturing efficiency and product range.
**Financial Performance**
Revenue£557K (H1 2024: £276K).
Gross Profit£303K (H1 2024: £111K).
Operating Loss£1.44m (H1 2024: £1.07m), including non-cash share-based payments of £486K.
Loss Before Tax£1.18m (H1 2024: £2.79m).
**Strategic Focus**
Expanding into the USA and Asia, with growing contributions from India and USA businesses.
Strengthening e-commerce and direct-to-consumer sales.
Reducing costs through negotiated IP cost reductions (30%) and operational efficiencies.
**Outlook**
Anticipated continued sales growth driven by 2024 launches, new partnerships, and e-commerce expansion.
Focus on achieving profitability and positive cash flow through cost control and margin improvements.
Launch of SweetBiotix and microbiome modulators in the US market expected to enhance visibility and liquidity.
**Management Commentary**
CEO Stephen OHara emphasized the company’s strong growth, cost reduction efforts, and strategic partnerships, positioning OptiBiotix for future revenue growth and profitability. The Board remains focused on building long-term shareholder value through innovative products and market expansion.
**Conclusion**
OptiBiotix Health PLC demonstrated robust financial and operational progress in H1 2025, with significant revenue growth, improved margins, and strategic advancements in key markets. The company is well-positioned to capitalize on emerging opportunities in the microbiome and health supplement sectors.